Plain-English translation of NCT06500637 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing whether , a new antibody medication, can safely improve the core symptoms of autism spectrum disorder in adults. The medication works by targeting a protein called Galectin-3, which researchers believe may be involved in brain inflammation associated with autism. The study will compare to a placebo (a dummy treatment) to see if the medication actually helps.
Recent research suggests that some people with autism may have higher levels of inflammation in the brain. Scientists believe this inflammation might contribute to autism symptoms, and this medication is designed to reduce that inflammation and improve how people with autism feel and function.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the medication or a placebo as an intravenous infusion (IV). You will need to attend all study visits with a caregiver, who will help complete questionnaires about your symptoms and behavior. Throughout the study, you must keep all your current treatments unchanged. The study includes regular check-ins to monitor your safety and how the treatment is working.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Rossignol Medical Center
Collaborators
Autism Discovery and Treatment Foundation
Enrollment target
~45 participants
Started
August 2024
Primary completion
December 2026
Age range
18 Years – 35 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alina Espinoza
Rossignol Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.